Literature DB >> 28746710

Clinical Outcomes of Metastatic Melanoma Treated With Checkpoint Inhibitors and Multisite Radiotherapy.

Jérôme Doyen1, Alexandra Picard2, Arash O Naghavi3, Antoine Thyss4, Thierry Passeron2, Jean-Philippe Lacour2, Henri Montaudié2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28746710      PMCID： PMC5817594          DOI： 10.1001/jamadermatol.2017.2222

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN： 2168-6068            Impact factor:   10.282


× No keyword cloud information.
  6 in total

1.  Immunologic correlates of the abscopal effect in a patient with melanoma.

Authors:  Michael A Postow; Margaret K Callahan; Christopher A Barker; Yoshiya Yamada; Jianda Yuan; Shigehisa Kitano; Zhenyu Mu; Teresa Rasalan; Matthew Adamow; Erika Ritter; Christine Sedrak; Achim A Jungbluth; Ramon Chua; Arvin S Yang; Ruth-Ann Roman; Samuel Rosner; Brenna Benson; James P Allison; Alexander M Lesokhin; Sacha Gnjatic; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2012-03-08       Impact factor: 91.245

Review 2.  Melanoma: Last call for radiotherapy.

Authors:  Sophie Espenel; Alexis Vallard; Chloé Rancoule; Max-Adrien Garcia; Jean-Baptiste Guy; Cyrus Chargari; Eric Deutsch; Nicolas Magné
Journal:  Crit Rev Oncol Hematol       Date:  2016-12-10       Impact factor: 6.312

3.  Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: Single centre subset analysis from a phase 1/2 trial.

Authors:  Antonin Levy; Christophe Massard; Jean-Charles Soria; Eric Deutsch
Journal:  Eur J Cancer       Date:  2016-10-17       Impact factor: 9.162

Review 4.  Targeted agents and immunotherapies: optimizing outcomes in melanoma.

Authors:  Jason J Luke; Keith T Flaherty; Antoni Ribas; Georgina V Long
Journal:  Nat Rev Clin Oncol       Date:  2017-04-04       Impact factor: 66.675

5.  Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma.

Authors:  E Liniker; A M Menzies; B Y Kong; A Cooper; S Ramanujam; S Lo; R F Kefford; G B Fogarty; A Guminski; T W Wang; M S Carlino; A Hong; G V Long
Journal:  Oncoimmunology       Date:  2016-08-19       Impact factor: 8.110

6.  Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy.

Authors:  K A Ahmed; Y A Abuodeh; M I Echevarria; J A Arrington; D G Stallworth; C Hogue; A O Naghavi; S Kim; Y Kim; B G Patel; S Sarangkasiri; P A S Johnstone; S Sahebjam; N I Khushalani; P A Forsyth; L B Harrison; M Yu; A B Etame; J J Caudell
Journal:  Ann Oncol       Date:  2016-09-15       Impact factor: 32.976
  6 in total
  4 in total

Review 1.  Neoadjuvant therapy of locally/regionally advanced melanoma.

Authors:  Arjun Khunger; Zachary S Buchwald; Michael Lowe; Mohammad K Khan; Keith A Delman; Ahmad A Tarhini
Journal:  Ther Adv Med Oncol       Date:  2019-07-31       Impact factor: 8.168

2.  Efficacy of Large Use of Combined Hypofractionated Radiotherapy in a Cohort of Anti-PD-1 Monotherapy-Treated Melanoma Patients.

Authors:  Philippe Saiag; Rafaele Molinier; Anissa Roger; Blandine Boru; Yves Otmezguine; Joelle Otz; Charles-Ambroise Valery; Astrid Blom; Christine Longvert; Alain Beauchet; Elisa Funck-Brentano
Journal:  Cancers (Basel)       Date:  2022-08-23       Impact factor: 6.575

3.  Efficacy of combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in difficult-to-treat advanced melanoma patients.

Authors:  Anissa Roger; Adeline Finet; Blandine Boru; Alain Beauchet; Jean-Jacques Mazeron; Yves Otzmeguine; Astrid Blom; Christine Longvert; Marie-Florence de Maleissye; Magali Fort; Elisa Funck-Brentano; Philippe Saiag
Journal:  Oncoimmunology       Date:  2018-03-13       Impact factor: 8.110

4.  Combined radiotherapy and immunotherapy in urothelial bladder cancer: harnessing the full potential of the anti-tumor immune response.

Authors:  Mame Daro-Faye; Wassim Kassouf; Luis Souhami; Gautier Marcq; Fabio Cury; Tamim Niazi; Paul Sargos
Journal:  World J Urol       Date:  2020-09-11       Impact factor: 4.226
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.